➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Baxter
Colorcon
Johnson and Johnson
Dow

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Pirarubicin


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Pirarubicin?

Pirarubicin is an investigational drug.

There have been 22 clinical trials for Pirarubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Breast Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Peking Union Medical College Hospital, and Peking University First Hospital.

There is one US patent protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for Pirarubicin
TitleSponsorPhase
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial CarcinomaUniversity of Texas Southwestern Medical CenterPhase 3
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyChinese Academy of Medical SciencesPhase 2
Combination Therapy of Anthracyclines for Children With NephroblastomaShengjing HospitalPhase 4

See all Pirarubicin clinical trials

Clinical Trial Summary for Pirarubicin

Top disease conditions for Pirarubicin
Top clinical trial sponsors for Pirarubicin

See all Pirarubicin clinical trials

US Patents for Pirarubicin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pirarubicin ⤷  Free Forever Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA) ⤷  Free Forever Trial
Pirarubicin ⤷  Free Forever Trial Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA) ⤷  Free Forever Trial
Pirarubicin ⤷  Free Forever Trial Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Free Forever Trial
Pirarubicin ⤷  Free Forever Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN) ⤷  Free Forever Trial
Pirarubicin ⤷  Free Forever Trial Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE) ⤷  Free Forever Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pirarubicin

Drugname Country Document Number Estimated Expiration Related US Patent
Pirarubicin Australia AU2006269422 2025-07-07 ⤷  Free Forever Trial
Pirarubicin Canada CA2614436 2025-07-07 ⤷  Free Forever Trial
Pirarubicin European Patent Office EP1917020 2025-07-07 ⤷  Free Forever Trial
Pirarubicin European Patent Office EP2722051 2025-07-07 ⤷  Free Forever Trial
Pirarubicin European Patent Office EP3498289 2025-07-07 ⤷  Free Forever Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Moodys
AstraZeneca
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.